Badar M. Mian, MD


Active surveillance data in prostate cancer show frequent upgrading, rare mortality

November 27, 2020

"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.